Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016

  • ID: 3635572
  • Report
  • 46 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Orbis Biosciences, Inc.
  • Xigen SA
  • MORE
Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016

Summary

The report ‘Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016’, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Sensorineural Hearing Loss and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Sensorineural Hearing Loss
- The report reviews pipeline therapeutics for Acute Sensorineural Hearing Loss by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Sensorineural Hearing Loss therapeutics and enlists all their major and minor projects
- The report assesses Acute Sensorineural Hearing Loss therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Sensorineural Hearing Loss

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Sensorineural Hearing Loss
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Sensorineural Hearing Loss pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Orbis Biosciences, Inc.
  • Xigen SA
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Acute Sensorineural Hearing Loss Overview

Therapeutics Development

Pipeline Products for Acute Sensorineural Hearing Loss - Overview

Acute Sensorineural Hearing Loss - Therapeutics under Development by Companies

Acute Sensorineural Hearing Loss - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Acute Sensorineural Hearing Loss - Products under Development by Companies

Acute Sensorineural Hearing Loss - Companies Involved in Therapeutics Development

Nordmark Arzneimittel GmbH & Co. KG

Orbis Biosciences, Inc.

Otologic Pharmaceutics, Inc.

Xigen SA

Acute Sensorineural Hearing Loss - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(acetylcysteine + disufenton sodium) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ancrod - Drug Profile

Product Description

Mechanism of Action

R&D Progress

betamethasone valerate ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Otopotin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Otostem - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Sensorineural Hearing Loss - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile

Product Description

Mechanism of Action

R&D Progress

XG-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Acute Sensorineural Hearing Loss - Recent Pipeline Updates

Acute Sensorineural Hearing Loss - Dormant Projects

Acute Sensorineural Hearing Loss - Product Development Milestones

Featured News & Press Releases

Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss

Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery

May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111

Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders

Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss

Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Sensorineural Hearing Loss, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Acute Sensorineural Hearing Loss - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H1 2016

Acute Sensorineural Hearing Loss - Pipeline by Orbis Biosciences, Inc., H1 2016

Acute Sensorineural Hearing Loss - Pipeline by Otologic Pharmaceutics, Inc., H1 2016

Acute Sensorineural Hearing Loss - Pipeline by Xigen SA, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Acute Sensorineural Hearing Loss Therapeutics - Recent Pipeline Updates, H1 2016

Acute Sensorineural Hearing Loss - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Acute Sensorineural Hearing Loss, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Nordmark Arzneimittel GmbH & Co. KG
Orbis Biosciences, Inc.
Otologic Pharmaceutics, Inc.
Xigen SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll